We are live on ! Find out more
ATYR

aTyr Pharma
ATYR

31 hedge funds and large institutions have $9.22M invested in aTyr Pharma in 2018 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 5 increasing their positions, 7 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

0.47% less ownership

Funds ownership: 3.18% → 2.71% (-0.47%)

6% less funds holding

Funds holding: 33 → 31 (-2)

24% less capital invested

Capital invested by funds: $12.1M → $9.22M (-$2.88M)

25% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 8

29% less repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 7

Holders
31
Holders Change
-2
Holders Change %
-6.06%
% of All Funds
0.71%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
6
Increased
5
Reduced
7
Closed
8
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$448K
2
Two Sigma Investments
Two Sigma Investments
New York
+$71.1K
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$57K
4
Acadian Asset Management
Acadian Asset Management
Massachusetts
+$50K
5
Millennium Management
Millennium Management
New York
+$25.2K

Top Sellers

Rank Fund Capital Flow
1
RG
Redmile Group
California
-$1.72M
2
Alyeska Investment Group
Alyeska Investment Group
Illinois
-$521K
3
Fidelity Investments
Fidelity Investments
Massachusetts
-$114K
4
BlackRock
BlackRock
New York
-$81K
5
Citadel Advisors
Citadel Advisors
Florida
-$35K
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$3.52M -$114K -10,419 -3%
PVMCV
2
Polaris Venture Management Co V
Massachusetts
$1.49M – – –
Viking Global Investors
3
Viking Global Investors
Connecticut
$1.13M – – –
Renaissance Technologies
4
Renaissance Technologies
New York
$899K +$448K +40,940 +107%
Vanguard Group
5
Vanguard Group
Pennsylvania
$551K +$6.34K +579 +1%
AG
6
Artal Group
Luxembourg
$406K – – –
BlackRock
7
BlackRock
New York
$169K -$81K -7,401 -33%
GHCM
8
Glen Harbor Capital Management
California
$125K – – –
MCIM
9
Meadow Creek Investment Management
Georgia
$103K – – –
Acadian Asset Management
10
Acadian Asset Management
Massachusetts
$99K +$50K +4,565 +110%
Geode Capital Management
11
Geode Capital Management
Massachusetts
$86K – – –
Two Sigma Investments
12
Two Sigma Investments
New York
$84K +$71.1K +6,499 +711%
BCM
13
Bridgeway Capital Management
Texas
$83K – – –
EP
14
Elkfork Partners
Oregon
$81K – – –
BFM
15
Boothbay Fund Management
New York
$77K -$8.06K -737 -10%
RCM
16
Riverhead Capital Management
Delaware
$65K – – –
TAM
17
Tyers Asset Management
Texas
$59K – – –
Susquehanna International Group
18
Susquehanna International Group
Pennsylvania
$59K +$57K +5,205 New
ARTA
19
A.R.T. Advisors
New York
$35K +$7.99K +730 +31%
Millennium Management
20
Millennium Management
New York
$26K +$25.2K +2,302 New
Northern Trust
21
Northern Trust
Illinois
$24K -$55 -5 -0.2%
PAM
22
Panagora Asset Management
Massachusetts
$15K -$635 -58 -4%
Jane Street
23
Jane Street
New York
$15K +$14.6K +1,338 New
Two Sigma Advisers
24
Two Sigma Advisers
New York
$10K +$9.15K +836 New
TSS
25
Two Sigma Securities
New York
$8K +$8.02K +733 New
1
2

ATYR Hedge Fund Activity: Q3 2018 in Review

31 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in aTyr Pharma (ATYR) for Q3 2018, worth a combined $9.22M — down 24% from $12.1M a quarter earlier.

Sellers outnumbered buyers: 8 funds closed out of ATYR and 6 opened new positions — a net loss of 2 holders — while 7 trimmed existing stakes and 5 added.

The largest buyer was Renaissance Technologies, adding an estimated $448K. The largest seller was Redmile Group, exiting entirely with an estimated $1.72M sold.

  • 31 institutional investors held aTyr Pharma (ATYR) as of Q3 2018, down from 33 in Q2 2018.
  • Funds reported $9.22M of aTyr Pharma stock for Q3 2018, down 24% quarter-over-quarter.
  • 6 funds opened new aTyr Pharma positions in Q3 2018 and 8 closed out, a net change of -2 holders.
  • The largest aTyr Pharma buyer in Q3 2018 was Renaissance Technologies, an estimated $448K added.
  • The largest aTyr Pharma seller in Q3 2018 was Redmile Group, an estimated $1.72M sold.

Based on aggregated 13F filings for Q3 2018.